GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab
A Randomized Phase 2 Study of the Safety, Efficacy, and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS-207 With or Without Nivolumab in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma
Sponsor: Aduro Biotech, Inc.
A PHASE2 clinical study on Previously Treated Metastatic Adenocarcinoma of the Pancreas, this trial is completed. The trial is conducted by Aduro Biotech, Inc. and has accumulated 12 data snapshots since 2015. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
May 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — May 2021 [monthly]
Completed PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 7 earlier versions
-
Feb 2020 — Mar 2020 [monthly]
Completed PHASE2
-
Nov 2019 — Feb 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Aug 2018 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Active Not Recruiting PHASE2
-
Aug 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Jan 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Aduro Biotech, Inc.
- American Association for Cancer Research
- Bristol-Myers Squibb
- Lustgarten Foundation
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Stand Up To Cancer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Baltimore, United States
- • Philadelphia, United States
- • Portland, United States
- • San Francisco, United States
- • Stanford, United States